MET and lung cancer: In addition, the frequency of c-Met gene amplification and mutation in human malignancies have been reported to range from 1.4 % to 7.2 % for gene amplification [19–21] and 1.7 % to 3.3 % for mutation [19, 21] in lung cancer, 1.5 % to 10.2 % for amplification in gastric cancer [14, 22, 23], 2 % for amplification in esophagogastric adenocarcinoma [24], 13.2 % for mutation in papillary renal carcinoma [25], and 26.7 % for mutation in head and neck squamous cell carcinoma [26].